|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
03.03.26 - 13:03
|
4basebio strengthens commercial leadership, promoting Christine Wolosin to Chief Commercial Officer (GlobeNewswire EN)
|
|
|
CAMBRIDGE, UK, 3 March 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the promotion of Christine Wolosin to Chief Commercial Officer. Christine, who joined 4basebio in September 2025 as Vice President, Business Development, will lead the Company's global commercial strategy, business development initiatives, and customer engagement as the Company scales its innovative synthetic DNA platform to serve the rapidly growing cell and gene therapy, mRNA, and vaccine markets....
|
|
|
16.02.26 - 08:06
|
Director Dealing (Cision)
|
|
|
16 February 2026
4basebio PLC
("4basebio" or the "Company")
Director Dealing
Cambridge, UK, 16 February 2026 – 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant GMP-grade synthetic DNA products, announces that on 13 February 2026 it was informed that Dr. Amy Walker, Chief Executive Officer of the Company made the following purchase in ordinary shares in the capital of the Company through the market.
Further details are set out in the Notification...
|
|
|
|
|
|
|
|
|
|
|
27.06.25 - 19:06
|
Result of AGM (Cision)
|
|
|
27 June 2025
4basebio PLC
("4basebio" or the "Company")
Result of AGM
Cambridge, UK, 25 June 2025 – 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform, announces the result of its Annual General Meeting held earlier today.
The Company decided at the meeting to make certain amendments to Resolutions 14 to 16 which were therefore withdrawn and replacement resolutions will be put forward in due course. All other resolutions were duly passed.
For further enquiries, please contact:...
|
|
|
25.06.25 - 08:06
|
Exercise of Options (Cision)
|
|
|
25 June 2025
4basebio PLC
("4basebio" or the "Company")
Exercise of Options
Cambridge, UK, 25 June 2025 – 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform, announces that, on 19 June 2025, it received notification from two employees of the Company to exercise EMI options over 13,000 ordinary shares (“New Ordinary Shares”) in the Company at an exercise price of £1.18 per share, raising total proceeds of £15,340.
Admission to AIM
Application will be made for the New Ordinary...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
